glp-1 medication risks compounding pharmacies GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists Not All Compounded GLP-1s Are

"GLP-1 receptor agonist medications should be started at the lowest dose, and escalated as tolerated or indicated." The case study points out the importance of testing for elevated blood ketones for those with type 1 using a GLP-1

No prescription is guaranteed

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate

S., Cali, A

45 Conversely, the relative increase in heart rates secondary to GLP-1 RAs may be potentially beneficial in HFpEF due to the high prevalence of chronotropic incompetence in these patients

State Medicaid programs and manufacturers were requested to submit their intentions to participate by January 8, 2026, and the model is expected to begin in May 2026